SUMMARY A randomised, within patient comparison was made in patients with severe chronic heart failure, to study the acute haemodynamic effects of oral agents which have inotropic and vasodilator properties. A non-glycosidic non-adrenergic positive inotropic agent with vasodilator properties (amrinone) was compared with a beta-agonist which has vasodilator and positive inotropic effects (pirbuterol). To assess whether combined treatment with a venodilator might be advantageous, the effect of adding isosorbide dinitrate was studied.
In chronic heart failure, conventional treatment with diuretics and digoxin often fails to relieve the symptoms of breathlessness and fatigue. This has led to the development of a range of new vasodilator and inotropic drugs,I-4 such as amrinone and pirbuterol.
Amrinone, a bipyridine derivative, is a positive inotropic agent in experimental preparations,5 6 and initial evaluation in man has shown its beneficial effects in heart failure after acute7-" l and chronic oral administration,12 13 both at rest and on exercise.' [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Its mode of action is unknown but it is unrelated to the inotropic effects of glycoside or catecholamine stimulation, or to changes in phosphodiesterase activity or cyclic AMP concentrations.578 Recent work with amrinone has suggested that, in man, a direct vasodilator effect may predominate over the positive inotropic action. ' 5 A serious adverse effect of Accepted for publication 30 November 1982 214 amrinone is thrombocytopenia,l6 which is reversible with reduction of drug dosage. '3 Pirbuterol is an orally active beta adrenergic agonist. Animal experiments have shown that it can exert a positive inotropic effect, '7 18 and also cause systemic vasodilatation. '8 In patients with heart failure, the predominant effect is probably vasodilatation, producing symptomatic and haemodynamic benefit after acute and chronic oral administration. '9-21 Few studies have compared the effects of positive inotropic and vasodilator drugs within the same patients with heart failure.'2 2223 We report a ran- 
Patients and methods
Thirteen patients who had been in clinical heart failure for three or more months were studied. They were 11 men and two women, with an average age of 62 years, range 44 to 77 years. The aetiology of heart failure was ischaemic heart disease in eight patients and dilated cardiomyopathy in five patients. All patients were severely symptomatic: four had dyspnoea at rest while nine had dyspnoea on mild exertion. There was radiological cardiomegaly (cardiothoracic ratio greater than 0.5) and pulmonary venous congestion in all patients despite diuretics (frusemide 80 to 250 mg daily, combined with spironolactone 100 mg or amiloride 10 to 20 mg daily). Only the four patients who were in atrial fibrillation received digoxin, for control of ventricular rate.
No patient was receiving vasodilators at the time of their study. Patients were studied during a stable phase of their illness, with a constant weight and no peripheral oedema. Informed consent was obtained in all cases. The patients were studied while supine, at rest, and without premedication, at least three hours after their usual morning medication. Right atrial, pulmonary arterial, and wedge pressures were recorded, using a triple-lumen, balloon-tipped, thermodilution catheter (CV1 model No. 600-017) positioned in the pulmonary artery, using the mid-chest as a zero reference point. Wedge A low oral dose of amrinone was used in this study in an attempt to avoid the problem of thrombocytopenia which, it has been suggested, may be a dose-related phenomenon. '2 Results ae expressed as means + SEM. Statistical analysis was performed using one-way analysis of variance, and when indicated, Students' t test for paired data.
Results
There were no significant changes in any variable during the control measurements, and control values were not significantly different before amrinone or pirbuterol were given.
After one hour, both drugs produced significant (p<O.Ol) increases in cardiac index and falls in left ventricular filling pressure and systemic vascular resistance ( Fig. 1 and 2 ). Heart rate was unchanged by either drug, so the increased cardiac index represents an increase in stroke volume (p<0.001). Blood pressure was not significantly altered by either drug.
Right atrial pressure fell slightly after each drug. The values at two-and-a-half hours were not significantly different from those at one hour, indicating that maximal changes had been achieved at the time that isosorbide dinitrate was added. After isosorbide dinitrate there were further falls in left ventricular filling pressure (p<0.01) and right atrial pressure (p<005) while blood pressure, systemic vascular resistance, and cardiac index did not change significantly, though there was individual variation in the effect on cardiac index.
The data have also been analysed to compare peak drug effect: for amrinone and pirbuterol this was defined as occurring in each patient at the time of greatest cardiac index, but for isosorbide dinitrate it was defined as occurring at the time of lowest left ventricular filling pressure (Fig. 3 to 5 and Table) .
After amrinone, the overall peak effect occurred at a mean of two hours, when cardiac index increased by 65%, left ventricular filling pressure fell by 27%, systemic vascular resistance fell by 33% (all p<0-001), and right atrial pressure fell by 16% (p<0-05).
After pirbuterol, peak effect occurred at a mean of one-and-a-half hours, when cardiac index increased tance, and cardiac index did not change significantly at peak effect of isosorbide dinitrate, with either drug.
There was wide individual variation in initial cardiac index, left ventricular filling pressure,-and systemic vascular resistance. There was less variation in response to amrinone and pirbuterol. There was less variability in the effect of isosorbide dinitrate on filling pressures and vascular resistance ( Fig. 6 to 8) . Unfortunately, pretreatment haemodynamic values could not predict any individual response to these drugs.
PLASMA AMRINONE LEVELS
Plasma amrinone concentrations, measured at the time of peak effect in seven of the patients, ranged from 0-56 to 1*33 ,ug/ml (mean 0-93+0-12 ,ug/ml). Though little is known of amrinone's pharmacokinetics in man, these concentrations are lower than those achieved by intravenous infusion or with larger oral doses of the drug,25 because we used a lower dose to avoid side effects.
PLASMA PIRBUTEROL LEVELS
Plasma pirbuterol concentrations were not measured in this study, because earlier work'9 has shown that an oral dose of 20 mg eight hourly produces almost maximal blood levels, sufficient to obtain maximal haemodynamic effect.
FOLLOW-UP AND ADVERSE EFFECTS
Eleven of the 13 patients reported subjective improvement during the studies. No adverse effects were noted during acute administration of any of the drugs, other than mild headache after isosorbide dinitrate. There was no angina and arrhythmias.
After the acute challenge, 10 of the patients began chronic treatment: seven receiving pirbuterol, 20 mg t.i.d., and three amrinone, 100 mg t.i.d. Of the patients continued on pirbuterol, two died within three months of refractory heart failure. No adverse effect was reported with pirbuterol, but one patient failed to improve clinically despite an initial response, and was therefore started on amrinone, with pronounced clinical improvement. Of the four patients who thus received amrinone chronically, one died of bronchopneumonia, and two had to be withdrawn because of adverse effects: intolerable gastrointenstinal disturbance in one and a thrombocytopenic reac- Fig. 6 Individual variation in cardiac index after amrinone, pirbuterol, and additional isosorbide dinitrate. A reduction in ventricular filling pressure is often attributed to venodilatation, though such an effect may also occur after arterial vasodilatation simply from the reduction in ventricular volumes. Though both amrinone and pirbuterol reduced ventricular filling pressures in our study, further reduction in ventricular filling pressure could be achieved with the predominant venodilator isosorbide dinitrate. This appears to be beneficial since the increased cardiac output was maintained with lower filling pressures. The addition of a nitrate should therefore be considered if breathlessness or pulmonary oedema are not corrected by amrinone or pirbuterol alone.
It is difficult to predict any possible long-term benefit with drugs in heart failure from their acute haemodynamic effects. Many complex considerations determine long-term benefit, including the natural progression of the disease, attenuation of drug action, and unwanted effects of the drugs. Whereas pirbuterol is well tolerated and has no serious adverse effects during chronic treatment, amrinone can cause thrombocytopenia even if a low dose is used.
There is no clear evidence as yet that treatment with any inotropic or vasodilator drug improves survival in chronic heart failure, but the patient's quality of life is often improved by such treatment. The careful use of these agents should be considered when conventional treatment fails to produce clinical improvement.
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